相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A bispecific immunotoxin (IHPP) with a long half-life targeting HER2 and PDGFRβ exhibited improved efficacy against HER2-positive tumors in a mouse xenograft model
Rui Guo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)
Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond
Romualdo Barroso-Sousa et al.
BIODRUGS (2021)
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Cornelius F. Waller et al.
BRITISH JOURNAL OF CANCER (2021)
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention
Bryan D. Fleming et al.
HEPATOLOGY (2020)
Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
Seiichiro Mitani et al.
CANCERS (2020)
Pathogenesis and Clinical Management of Uterine Serous Carcinoma
Li Zhang et al.
CANCERS (2020)
Silence of TPPP3 suppresses cell proliferation, invasion and migration via inactivating NF-κB/COX2 signal pathway in breast cancer cell
Qianfeng Ren et al.
CELL BIOCHEMISTRY AND FUNCTION (2020)
Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation
Ronit Mazor et al.
FRONTIERS IN IMMUNOLOGY (2020)
Antibody-Drug Conjugates: The Last Decade
Nicolas Joubert et al.
PHARMACEUTICALS (2020)
Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design
Nam-Kyung Lee et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Targeted Diphtheria Toxin-Based Therapy: A Review Article
Fatemeh Shafiee et al.
FRONTIERS IN MICROBIOLOGY (2019)
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
Zhuyu Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Moxetumomab Pasudotox: First Global Approval
Sohita Dhillon
DRUGS (2018)
TPPP3 Promotes Cell Proliferation, Invasion and Tumor Metastasis via STAT3/Twist1 Pathway in Non-Small-Cell Lung Carcinoma
Yintao Li et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy
Thomas Mehrling et al.
ANTIBODIES (2018)
Bicyclic Peptides as Next-Generation Therapeutics
Curran A. Rhodes et al.
CHEMISTRY-A EUROPEAN JOURNAL (2017)
HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity
Rui Guo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Jennifer L. Hsu et al.
CANCER AND METASTASIS REVIEWS (2016)
Fusion of an albumin-binding domain extends the half-life of immunotoxins
Rui Guo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research
Natini Jinawath et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
Ronit Mazor et al.
ONCOTARGET (2016)
Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain
Hao Liu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Building better monoclonal antibody-based therapeutics
George J. Weiner
NATURE REVIEWS CANCER (2015)
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Laleh Amiri-Kordestani et al.
CLINICAL CANCER RESEARCH (2014)
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
Ronit Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression
Beiqin Yu et al.
BMC CELL BIOLOGY (2013)
Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?
J. T. Ribeiro et al.
ANNALS OF ONCOLOGY (2012)
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
Wenhai Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Monoclonal antibodies for the treatment of cancer
Casey W. Shuptrine et al.
SEMINARS IN CANCER BIOLOGY (2012)
HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors
Rafal Zielinski et al.
CLINICAL CANCER RESEARCH (2011)
Anti-HER agents in gastric cancer: from bench to bedside
Lorenzo Fornaro et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
Design of an Optimized Scaffold for Affibody Molecules
Joachim Feldwisch et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
分享论文
